

# Fragile X Syndrome-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/F51F4E333BDEN.html>

Date: February 2018

Pages: 137

Price: US\$ 3,480.00 (Single User License)

ID: F51F4E333BDEN

## Abstracts

### Report Summary

Fragile X Syndrome-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Fragile X Syndrome industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Fragile X Syndrome 2013-2017, and development forecast 2018-2023

Main market players of Fragile X Syndrome in United States, with company and product introduction, position in the Fragile X Syndrome market

Market status and development trend of Fragile X Syndrome by types and applications

Cost and profit status of Fragile X Syndrome, and marketing status

Market growth drivers and challenges

The report segments the United States Fragile X Syndrome market as:

United States Fragile X Syndrome Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

## Southwest

United States Fragile X Syndrome Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

ACT-01  
AMO-01  
ANAVEX-273  
AUT-00206  
Bryostatin-1  
Cannabidiol  
Others

United States Fragile X Syndrome Market: Application Segment Analysis (Consumption  
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Clinic  
Hopital  
Research Center

United States Fragile X Syndrome Market: Players Segment Analysis (Company and  
Product introduction, Fragile X Syndrome Sales Volume, Revenue, Price and Gross  
Margin):

Aelis Farma SAS  
Alcobra Ltd  
AMO Pharma Limited  
Confluence Pharmaceuticals LLC  
Eli Lilly and Company  
F. Hoffmann-La Roche Ltd.  
Marinus Pharmaceuticals, Inc.  
MI.TO. Technology S.r.L.  
Neuren Pharmaceuticals Limited  
Ovid Therapeutics Inc.  
Sage Therapeutics, Inc.  
Zynerba Pharmaceuticals, Inc.

In a word, the report provides detailed statistics and analysis on the state of the  
industry; and is a valuable source of guidance and direction for companies and

individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF FRAGILE X SYNDROME**

- 1.1 Definition of Fragile X Syndrome in This Report
- 1.2 Commercial Types of Fragile X Syndrome
  - 1.2.1 ACT-01
  - 1.2.2 AMO-01
  - 1.2.3 ANAVEX-273
  - 1.2.4 AUT-00206
  - 1.2.5 Bryostatin-1
  - 1.2.6 Cannabidiol
  - 1.2.7 Others
- 1.3 Downstream Application of Fragile X Syndrome
  - 1.3.1 Clinic
  - 1.3.2 Hopital
  - 1.3.3 Research Center
- 1.4 Development History of Fragile X Syndrome
- 1.5 Market Status and Trend of Fragile X Syndrome 2013-2023
  - 1.5.1 United States Fragile X Syndrome Market Status and Trend 2013-2023
  - 1.5.2 Regional Fragile X Syndrome Market Status and Trend 2013-2023

### **CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Fragile X Syndrome in United States 2013-2017
- 2.2 Consumption Market of Fragile X Syndrome in United States by Regions
  - 2.2.1 Consumption Volume of Fragile X Syndrome in United States by Regions
  - 2.2.2 Revenue of Fragile X Syndrome in United States by Regions
- 2.3 Market Analysis of Fragile X Syndrome in United States by Regions
  - 2.3.1 Market Analysis of Fragile X Syndrome in New England 2013-2017
  - 2.3.2 Market Analysis of Fragile X Syndrome in The Middle Atlantic 2013-2017
  - 2.3.3 Market Analysis of Fragile X Syndrome in The Midwest 2013-2017
  - 2.3.4 Market Analysis of Fragile X Syndrome in The West 2013-2017
  - 2.3.5 Market Analysis of Fragile X Syndrome in The South 2013-2017
  - 2.3.6 Market Analysis of Fragile X Syndrome in Southwest 2013-2017
- 2.4 Market Development Forecast of Fragile X Syndrome in United States 2018-2023
  - 2.4.1 Market Development Forecast of Fragile X Syndrome in United States 2018-2023
  - 2.4.2 Market Development Forecast of Fragile X Syndrome by Regions 2018-2023

## **CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Whole United States Market Status by Types

#### 3.1.1 Consumption Volume of Fragile X Syndrome in United States by Types

#### 3.1.2 Revenue of Fragile X Syndrome in United States by Types

### 3.2 United States Market Status by Types in Major Countries

#### 3.2.1 Market Status by Types in New England

#### 3.2.2 Market Status by Types in The Middle Atlantic

#### 3.2.3 Market Status by Types in The Midwest

#### 3.2.4 Market Status by Types in The West

#### 3.2.5 Market Status by Types in The South

#### 3.2.6 Market Status by Types in Southwest

### 3.3 Market Forecast of Fragile X Syndrome in United States by Types

## **CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

### 4.1 Demand Volume of Fragile X Syndrome in United States by Downstream Industry

### 4.2 Demand Volume of Fragile X Syndrome by Downstream Industry in Major Countries

#### 4.2.1 Demand Volume of Fragile X Syndrome by Downstream Industry in New England

#### 4.2.2 Demand Volume of Fragile X Syndrome by Downstream Industry in The Middle Atlantic

#### 4.2.3 Demand Volume of Fragile X Syndrome by Downstream Industry in The Midwest

#### 4.2.4 Demand Volume of Fragile X Syndrome by Downstream Industry in The West

#### 4.2.5 Demand Volume of Fragile X Syndrome by Downstream Industry in The South

#### 4.2.6 Demand Volume of Fragile X Syndrome by Downstream Industry in Southwest

### 4.3 Market Forecast of Fragile X Syndrome in United States by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF FRAGILE X SYNDROME**

### 5.1 United States Economy Situation and Trend Overview

### 5.2 Fragile X Syndrome Downstream Industry Situation and Trend Overview

## **CHAPTER 6 FRAGILE X SYNDROME MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES**

### 6.1 Sales Volume of Fragile X Syndrome in United States by Major Players

- 6.2 Revenue of Fragile X Syndrome in United States by Major Players
- 6.3 Basic Information of Fragile X Syndrome by Major Players
  - 6.3.1 Headquarters Location and Established Time of Fragile X Syndrome Major Players
  - 6.3.2 Employees and Revenue Level of Fragile X Syndrome Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 FRAGILE X SYNDROME MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Aelis Farma SAS
  - 7.1.1 Company profile
  - 7.1.2 Representative Fragile X Syndrome Product
  - 7.1.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Aelis Farma SAS
- 7.2 Alcobra Ltd
  - 7.2.1 Company profile
  - 7.2.2 Representative Fragile X Syndrome Product
  - 7.2.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Alcobra Ltd
- 7.3 AMO Pharma Limited
  - 7.3.1 Company profile
  - 7.3.2 Representative Fragile X Syndrome Product
  - 7.3.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of AMO Pharma Limited
- 7.4 Confluence Pharmaceuticals LLC
  - 7.4.1 Company profile
  - 7.4.2 Representative Fragile X Syndrome Product
  - 7.4.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Confluence Pharmaceuticals LLC
- 7.5 Eli Lilly and Company
  - 7.5.1 Company profile
  - 7.5.2 Representative Fragile X Syndrome Product
  - 7.5.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
- 7.6 F. Hoffmann-La Roche Ltd.
  - 7.6.1 Company profile

- 7.6.2 Representative Fragile X Syndrome Product
- 7.6.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
- 7.7 Marinus Pharmaceuticals, Inc.
  - 7.7.1 Company profile
  - 7.7.2 Representative Fragile X Syndrome Product
  - 7.7.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Marinus Pharmaceuticals, Inc.
- 7.8 MI.TO. Technology S.r.L.
  - 7.8.1 Company profile
  - 7.8.2 Representative Fragile X Syndrome Product
  - 7.8.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of MI.TO. Technology S.r.L.
- 7.9 Neuren Pharmaceuticals Limited
  - 7.9.1 Company profile
  - 7.9.2 Representative Fragile X Syndrome Product
  - 7.9.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Neuren Pharmaceuticals Limited
- 7.10 Ovid Therapeutics Inc.
  - 7.10.1 Company profile
  - 7.10.2 Representative Fragile X Syndrome Product
  - 7.10.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Ovid Therapeutics Inc.
- 7.11 Sage Therapeutics, Inc.
  - 7.11.1 Company profile
  - 7.11.2 Representative Fragile X Syndrome Product
  - 7.11.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Sage Therapeutics, Inc.
- 7.12 Zynerba Pharmaceuticals, Inc.
  - 7.12.1 Company profile
  - 7.12.2 Representative Fragile X Syndrome Product
  - 7.12.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Zynerba Pharmaceuticals, Inc.

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF FRAGILE X SYNDROME**

- 8.1 Industry Chain of Fragile X Syndrome
- 8.2 Upstream Market and Representative Companies Analysis

### 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF FRAGILE X SYNDROME**

### 9.1 Cost Structure Analysis of Fragile X Syndrome

### 9.2 Raw Materials Cost Analysis of Fragile X Syndrome

### 9.3 Labor Cost Analysis of Fragile X Syndrome

### 9.4 Manufacturing Expenses Analysis of Fragile X Syndrome

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF FRAGILE X SYNDROME**

### 10.1 Marketing Channel

#### 10.1.1 Direct Marketing

#### 10.1.2 Indirect Marketing

#### 10.1.3 Marketing Channel Development Trend

### 10.2 Market Positioning

#### 10.2.1 Pricing Strategy

#### 10.2.2 Brand Strategy

#### 10.2.3 Target Client

### 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

### 12.1 Methodology/Research Approach

#### 12.1.1 Research Programs/Design

#### 12.1.2 Market Size Estimation

#### 12.1.3 Market Breakdown and Data Triangulation

### 12.2 Data Source

#### 12.2.1 Secondary Sources

#### 12.2.2 Primary Sources

### 12.3 Reference



## I would like to order

Product name: Fragile X Syndrome-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/F51F4E333BDEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F51F4E333BDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970